All Stories

  1. Intravenous [Pyr¹]apelin-13 in Healthy Volunteers with Artificially-Induced Syndrome of Inappropriate Antidiuresis - a double-blind, randomised, placebo-controlled crossover study
  2. Bidirectional Crosstalk Between Vulnerable Coronary Plaque and Coronary Microvascular Dysfunction: A Narrative Review
  3. International Union of Basic and Clinical Pharmacology. XXXX. Apelin Receptor Pharmacology in the Human Cardiovascular System and Emerging Clinical Applications.
  4. Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system
  5. Analysis of the expression of genes encoding the endothelin signaling pathway in fetal, heathy, and diseased adult human heart using single-cell transcriptomics
  6. Comparison of endothelin-1 levels in plasma from human coronary arteries measured by enzyme linked immunosorbent assay and Olink high-throughput proteomics platform
  7. The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors
  8. The Concise Guide to PHARMACOLOGY 2025/26: Introduction and Other Protein Targets
  9. Bile acid receptor in GtoPdb v.2025.3
  10. Chemerin receptors in GtoPdb v.2025.3
  11. Ghrelin receptor in GtoPdb v.2025.3
  12. Succinate receptor in GtoPdb v.2025.3
  13. Trace amine receptor in GtoPdb v.2025.3
  14. Apelin receptor in GtoPdb v.2025.3
  15. Endothelin receptors in GtoPdb v.2025.3
  16. Short communications: Endothelin-1 in cardiac allograft vasculopathy
  17. Cardiovascular and renal effects of apelin in chronic kidney disease: a randomised, double-blind, placebo-controlled, crossover study
  18. Microarray analysis demonstrates up-regulation of the endothelin-1 gene with compensatory down-regulation of the ETA receptor gene in human portal vein
  19. Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?
  20. Co-localization of the sodium-glucose co-transporter-2 channel (SGLT-2) with endothelin ETA and ETB receptors in human cardiorenal tissue
  21. Structural and functional determination of peptide versus small molecule ligand binding at the apelin receptor
  22. Targeting the apelin system for the treatment of cardiovascular diseases
  23. Current and future strategies for targeting the endothelin pathway in cardiovascular disease
  24. The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
  25. Urotensin receptor in GtoPdb v.2023.1
  26. Trace amine receptor in GtoPdb v.2023.1
  27. Thyrotropin-releasing hormone receptors in GtoPdb v.2023.1
  28. Class A Orphans in GtoPdb v.2023.1
  29. Motilin receptor in GtoPdb v.2023.1
  30. Neuropeptide W/neuropeptide B receptors in GtoPdb v.2023.1
  31. Endothelin receptors in GtoPdb v.2023.1
  32. Kisspeptin receptor in GtoPdb v.2023.1
  33. Succinate receptor in GtoPdb v.2023.1
  34. Apelin receptor in GtoPdb v.2023.1
  35. Bile acid receptor in GtoPdb v.2023.1
  36. QRFP receptor in GtoPdb v.2023.1
  37. Ghrelin receptor in GtoPdb v.2023.1
  38. Chemerin receptors in GtoPdb v.2023.1
  39. Oxoglutarate receptor in GtoPdb v.2023.1
  40. Class A Orphans in GtoPdb v.2022.3
  41. Trans-myocardial Extraction of Endothelin-1 Correlates with Increased Microcirculatory Resistance following Percutaneous Coronary Intervention
  42. In vitro metabolism of synthetic Elabela/Toddler (ELA-32) peptide in human plasma and kidney homogenates analyzed with mass spectrometry and validation of endogenous peptide quantification in tissues by ELISA
  43. The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials
  44. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
  45. Class A Orphans in GtoPdb v.2021.3
  46. Urotensin receptor in GtoPdb v.2021.3
  47. Succinate receptor in GtoPdb v.2021.3
  48. Ghrelin receptor in GtoPdb v.2021.3
  49. Chemerin receptors in GtoPdb v.2021.3
  50. The therapeutic potential of apelin in kidney disease
  51. Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection
  52. Motilin receptor in GtoPdb v.2021.2
  53. Human embryonic stem cell-derived cardiomyocytes express SARS-CoV-2 host entry proteins: screen to identify inhibitors of infection
  54. Class A Orphans (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database
  55. Motilin receptor (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database
  56. Kisspeptin receptor (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database
  57. Genes Encoding ACE2, TMPRSS2 and Related Proteins Mediating SARS-CoV-2 Viral Entry are Upregulated with Age in Human Cardiomyocytes
  58. A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development. IUPHAR Review 29
  59. Advances in therapeutic peptides targeting G protein-coupled receptors
  60. Class A Orphans (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database
  61. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors
  62. Apelin-36-[L28A] and Apelin-36-[L28C(30kDa-PEG)] peptides that improve diet induced obesity are G protein biased ligands at the apelin receptor
  63. QRFP receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  64. Class A Orphans (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  65. Bile acid receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  66. Apelin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  67. Oxoglutarate receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  68. Chemerin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  69. Ghrelin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  70. Endothelin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  71. Kisspeptin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  72. Motilin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  73. Neuropeptide W/neuropeptide B receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  74. Succinate receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  75. Thyrotropin-releasing hormone receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  76. Trace amine receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  77. Urotensin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  78. International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand
  79. International Union of Basic and Clinical Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) Nomenclature, Pharmacology, and Function
  80. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors
  81. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview
  82. Pharmacological targeting of apelin impairs glioblastoma growth
  83. Detection of Atherosclerotic Inflammation by 68 Ga-DOTATATE PET Compared to [ 18 F]FDG PET Imaging
  84. Vascular Imaging With 18 F-Fluorodeoxyglucose Positron Emission Tomography Is Influenced by Hypoxia
  85. 18 F-Fluoride and 18 F-Fluorodeoxyglucose Positron Emission Tomography After Transient Ischemic Attack or Minor Ischemic StrokeCLINICAL PERSPECTIVE
  86. [Pyr1]Apelin-13(1–12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13
  87. Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial HypertensionClinical Perspective
  88. OUP accepted manuscript
  89. Smooth Muscle Endothelin B Receptors Regulate Blood Pressure but Not Vascular Function or Neointimal RemodelingNovelty and Significance
  90. Chemerin Elicits Potent Constrictor Actions via Chemokine‐Like Receptor 1 (CMKLR1), not G‐Protein‐Coupled Receptor 1 (GPR1), in Human and Rat Vasculature
  91. Cardiac action of the first G protein biased small molecule apelin agonist
  92. Endothelin ETA receptors predominate in chronic thromboembolic pulmonary hypertension
  93. The endothelin hormones, structure and function
  94. The Prodomain-bound Form of Bone Morphogenetic Protein 10 Is Biologically Active on Endothelial Cells
  95. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors
  96. The Concise Guide to PHARMACOLOGY 2015/16: Overview
  97. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands
  98. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system
  99. Identifying active vascular microcalcification by 18F-sodium fluoride positron emission tomography
  100. LGR5 Activates Noncanonical Wnt Signaling and Inhibits Aldosterone Production in the Human Adrenal
  101. Endothelin Receptors and Their Antagonists
  102. Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist
  103. Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12
  104. Changes in biomechanical properties of the coronary artery wall contribute to maintained contractile responses to endothelin-1 in atherosclerosis
  105. Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension
  106. In Vivo Mapping of Vascular Inflammation Using the Translocator Protein Tracer 18 F-FEDAA1106
  107. Characterization of [125I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta
  108. The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro
  109. The Concise Guide to PHARMACOLOGY 2013/14: Overview
  110. The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
  111. Evolving pharmacology of orphan GPCRs: IUPHAR Commentary
  112. No evidence for a local renin-angiotensin system in liver mitochondria
  113. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension
  114. Screening β-Arrestin Recruitment for the Identification of Natural Ligands for Orphan G-Protein–Coupled Receptors
  115. International Union of Basic and Clinical Pharmacology. LXXXVIII. G Protein-Coupled Receptor List: Recommendations for New Pairings with Cognate Ligands
  116. Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer
  117. Themed section: endothelin
  118. IUPHAR-DB: updated database content and new features
  119. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans
  120. Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice
  121. Comparison of human ETA and ETB receptor signalling via G-protein and β-arrestin pathways
  122. Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues
  123. The Twelfth International Conference on Endothelin (ET-12), Cambridge 2011
  124. GuideToPharmacology.org - an update
  125. Cellular Localization of Receptors Using Antibodies Visualized by Light and Dual Labeling Confocal Microscopy
  126. Dynamic In Vivo Imaging of Receptors in Small Animals Using Positron Emission Tomography
  127. How to Use the IUPHAR Receptor Database to Navigate Pharmacological Data
  128. Quantitative Phosphor Imaging Autoradiography of Radioligands for Positron Emission Tomography
  129. Radioligand Binding Assays and Their Analysis
  130. Receptor Binding Techniques
  131. Inotropic Action of the Puberty Hormone Kisspeptin in Rat, Mouse and Human: Cardiovascular Distribution and Characteristics of the Kisspeptin Receptor
  132. Importance of Subtype Selectivity for Endothelin Receptor Antagonists in the Human Vasculature
  133. Discovery of a Competitive Apelin Receptor (APJ) Antagonist
  134. Chemokine receptor CCR5: from AIDS to atherosclerosis
  135. Pharmacology of Renal Endothelin Receptors
  136. International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin Receptor Nomenclature, Distribution, and Function
  137. Evidence for a novel vasospastic transmitter system, neuromedin U, in the equine digital circulation
  138. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin Receptor Nomenclature, Distribution, Pharmacology, and Function
  139. Endothelial cell-specific ETBreceptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1This article is one of a selection of papers published in the two-part special issue entitled 20 Years o...
  140. Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis
  141. Introduction
  142. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man
  143. Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver
  144. EDITORIAL
  145. The endothelin system in pulmonary and renal vasculopathy: les liaisons dangereuses
  146. FDG–PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis
  147. Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S
  148. [Pyr1]Apelin-13 Identified as the Predominant Apelin Isoform in the Human Heart: Vasoactive Mechanisms and Inotropic Action in Disease
  149. International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature
  150. Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation
  151. Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system
  152. Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ETB receptors in vivo
  153. Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system
  154. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels
  155. Automated synthesis of the generic peptide labelling agent N-succinimidyl 4-[18F]fluorobenzoate and application to 18F-label the vasoactive transmitter urotensin-II as a ligand for positron emission tomography
  156. Chronic Apoptosis of Vascular Smooth Muscle Cells Accelerates Atherosclerosis and Promotes Calcification and Medial Degeneration
  157. Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: Relevance to function
  158. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease
  159. Strategy for improved [11C]DAA1106 radiosynthesis and in vivo peripheral benzodiazepine receptor imaging using microPET, evaluation of [11C]DAA1106
  160. Kisspeptins Are Novel Potent Vasoconstrictors in Humans, with a Discrete Localization of Their Receptor, G Protein-Coupled Receptor 54, to Atherosclerosis-Prone Vessels
  161. Endothelin Receptors
  162. Urotensin-II Receptor
  163. ET-B Endothelin Receptor
  164. ET-A Endothelin Receptor
  165. Characterization of the snake venom ligand [125I]-DNP binding to natriuretic peptide receptor-A in human artery and potent DNP mediated vasodilatation
  166. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis
  167. Neuropeptide B and W: neurotransmitters in an emerging G-protein-coupled receptor system
  168. Novel Snake Venom Ligand Dendroaspis Natriuretic Peptide Is Selective for Natriuretic Peptide Receptor-A in Human Heart: Downregulation of Natriuretic Peptide Receptor-A in Heart Failure
  169. Deletion of Endothelial Cell Endothelin B Receptors Does Not Affect Blood Pressure or Sensitivity to Salt
  170. Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man
  171. International Union of Pharmacology. LVI. Ghrelin Receptor Nomenclature, Distribution, and Function
  172. Triptan-induced contractile (5-HT1Breceptor) responses in human cerebral and coronary arteries: relationship to clinical effect
  173. Emerging roles of apelin in biology and medicine
  174. Regulation of vascular reactivity by established and emerging GPCRs
  175. International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List
  176. Receptor Binding Techniques
  177. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells
  178. Alternative Pathway to Endothelin-Converting Enzyme for the Synthesis of Endothelin in Human Blood Vessels
  179. Comparison of Endothelin-A and Endothelin-B Receptor Distribution Visualized by Radioligand Binding versus Immunocytochemical Localization using Subtype Selective Antisera
  180. Down-regulation of ETA Receptors in ETB Receptor-deficient Mice
  181. Endothelin Receptor Pharmacology and Function in the Mouse: Comparison with Rat and Man
  182. In Vivo Imaging of Cardiovascular Endothelin Receptors Using the Novel Radiolabelled Antagonist [18F]-SB209670 and Positron Emission Tomography (microPET)
  183. CRF2receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators
  184. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries
  185. Regional Hemodynamic Actions of Selective Corticotropin-Releasing Factor Type 2 Receptor Ligands in Conscious Rats
  186. Identification and cellular localisation of NPW1 (GPR7) receptors for the novel neuropeptide W-23 by [125I]-NPW radioligand binding and immunocytochemistry
  187. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells
  188. Maternal Dexamethasone Increases Endothelin-1 Sensitivity and Endothelin A Receptor Expression in Ovine Foetal Placental Arteries
  189. Peptide and trace amine orphan receptors: prospects for new therapeutic targets
  190. Translating the human genome: renaissance of cardiovascular receptor pharmacology
  191. Emerging roles for orphan G-protein-coupled receptors in the cardiovascular system
  192. Life before birth: effects of cortisol on future cardiovascular and metabolic function*
  193. Is urotensin-II the new endothelin?
  194. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1
  195. Peptide Research Protocols
  196. International Union of Pharmacology. XXIX. Update on Endothelin Receptor Nomenclature
  197. Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography
  198. Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system
  199. Of mice and men: advances in endothelin research and first antagonist gains FDA approval
  200. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors
  201. Radioligand binding reveals chymase as the predominant enzyme for mediating tissue conversion of angiotensin I in the normal human heart
  202. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT1receptor antagonist losartan
  203. Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteriesin vitro
  204. [125I-His9]-Ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue; up-regulation of receptors with atherosclerosis
  205. Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery
  206. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats
  207. The endothelin system in human saphenous vein graft disease
  208. [125I]-(Pyr1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man
  209. Nitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system
  210. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1
  211. Endothelin receptor antagonism in patients with chronic heart failure
  212. Urotensin II: fish neuropeptide catches orphan receptor
  213. Preface
  214. Cellular Expression of Isoforms of Endothelin-Converting Enzyme-1 (ECE-1c, ECE-1b and ECE-1a) and Endothelin-Converting Enzyme-2
  215. Changes in ETA-, AT1- and AT2-Receptors in the Phenotypically Transformed Intimal Smooth Muscle Layer of Human Atherosclerotic Coronary Arteries
  216. Endothelin-A-Receptors in Human Aorta and Pulmonary Arteries are Downregulated in Patients With Cardiovascular Disease
  217. Expression and Characterization of the Human Endothelin-A-Receptor in Pichia pastoris
  218. No Alteration in Vasoconstrictor Endothelin-B-Receptor Density or Function in Human Coronary Artery Disease
  219. Novel Nitric Oxide Donors Reverse Endothelin-1-Mediated Constriction in Human Blood Vessels
  220. Syntheses of the First Endothelin-A- and -B-Selective Radioligands for Positron Emission Tomography
  221. Tissue-Specific Modulation of Endothelin Receptors in a Rat Model of Hypertension
  222. Evidence for Intracellular Endothelin-Converting Enzyme-2 Expression in Cultured Human Vascular Endothelial Cells
  223. Blockade and Reversal of Endothelin-Induced Constriction in Pial Arteries From Human Brain   Editorial Comment
  224. Endothelin receptor expression and pharmacology in human saphenous vein graft
  225. Secretory pathways in endothelin synthesis
  226. The therapeutic potential of PD156707 and related butenolide endothelin antagonists
  227. The haemodynamic effects of iodinated water soluble radiographic contrast media: a review
  228. Expression of EndothelinA Receptors in Human Gliomas and Meningiomas, with High Affinity for the Selective Antagonist PD156707
  229. Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease
  230. Human Endothelial Cell Storage Granules : A Novel Intracellular Site for Isoforms of the Endothelin-Converting Enzyme
  231. Endothelin receptor subtypes and their functional relevance in human small coronary arteries
  232. Evidence Using Immunoelectron Microscopy for Regulated and Constitutive Pathways in the Transport and Release of Endothelin
  233. In vitro enzymatic processing of radiolabelled big ET-1 in human kidney
  234. Characterization of [125I]-PD164333, an ETAselective non-peptide radiolabelled antagonist, in normal and diseased human tissues
  235. Characterization of Site-Directed Antisera Against Endothelin-Converting Enzymes
  236. Endothelin Peptide and Converting Enzymes in Human Endothelium
  237. Endothelin-Converting Enzyme in the Human Vasculature: Evidence for Differential Conversion of Big Endothelin-3 by Endothelial and Smooth-Muscle Cells
  238. PD156707: A Potent Antagonist of Endothelin-1 in Human Diseased Coronary Arteries and Vein Grafts
  239. Relative Contribution of Endothelin A and Endothelin B Receptors to Vasoconstriction in Small Arteries from Human Heart and Brain
  240. Endothelin converting enzyme (ECE) activity in human vascular smooth muscle
  241. Detection of Endothelin Receptors in Human Coronary Artery Vascular Smooth Muscle Cells But Not Endothelial Cells by Using Electron Microscope Autoradiography
  242. Differential distribution of endothelin receptor subtypes in placentae from normal and growth-restricted pregnancies
  243. Differential distribution of endothelin peptides and receptors in human adrenal gland
  244. Characterization of the binding of endothelin ETB selective ligands in human and rat heart
  245. Endothelin Peptide and Receptors in Human Atherosclerotic Coronary Artery and Aorta
  246. Selective downregulation of ETA receptor mRNA in renal transplant recipients on cyclosporin A revealed by quantitative RT-PCR
  247. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044
  248. Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments
  249. The endothelin system in the kidney
  250. Endothelin receptors in human coronary artery and aorta
  251. Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart
  252. Localization of endothelin peptides in human kidney
  253. Endocrinology and paracrinology
  254. Radioligand Binding Assays: Theory and Practice
  255. Expression of Endothelin Peptides and Mrna in the Human Heart
  256. Endothelin ETA receptor expression in human cerebrovascular smooth muscle cells
  257. Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm
  258. Endothelin expression in the uterus
  259. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro
  260. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type
  261. ETA and ETB endothelin receptors in human myometrium characterized by the subtype selective ligands BQ123, BQ3020, FR139317 and PD151242
  262. Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells
  263. Selectivity of [125I]-PD 151242 for human, rat and porcine endothelin ETA receptors in the heart
  264. [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature
  265. Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro
  266. Quantification of mRNA in Human Tissue Using Fluorescent Nested Reverse-Transcriptase Polymerase Chain Reaction
  267. Effects of Phosphoramidon and Pepstatin a on the Secretion of Endothelin-I and Big Endothelin-I by Human Umbilical Vein Endothelial Cells: Measurement by Two-Site Enzyme-Linked Immunosorbent Assays
  268. Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats
  269. Davenport and Maguire reply
  270. Validation of mRNA Quantification in Human Kidney by a Novel Fluorescent Nested RT-PCR Method
  271. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans?
  272. [125I]-PD 151242: a selective radioligand for human ETA receptors
  273. Isolation of Human Cardiac Endothelin Receptors by a Peptide-Receptor Mobility Shift Assay
  274. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney
  275. Alternatively Spliced mRNAs for Human Endothelin-2 and Their Tissue Distribution
  276. Endothelin: progress in pharmacology and physiology
  277. Identification of endothelin-1, endothelin-2 and endothelin-3 in human endometrium
  278. Characterisation of Immunoreactive Endothelin in Human kidney by RP-HPLC and RIA
  279. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium
  280. Quantitative autoradiography reveals higher densities of specific calcitonin-gene-related peptide receptors in small intramyocardial compared with large epicardial coronary arteries
  281. Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in human endometrium and a change in the ratio of ETA and ETB receptor subtype across the menstrual cycle.
  282. Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in human endometrium and a change in the ratio of ETA and ETB receptor subtype across the menstrual cycle
  283. Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart
  284. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue
  285. Localization of immunoreactive endothelin and proendothelin in the human lung
  286. Endothelin-like immunoreactivity in human endometrium
  287. Cerebellar neurons and glia respond differentially to endothelins and sarafotoxin S6b
  288. Endothelins in reproduction
  289. Localization and endogenous concentration of endothelin-like immunoreactivity in human placenta
  290. Epidermal growth factor in human endometrium: proliferative effects in culture and immunocytochemical localization in normal and endometriotic tissues
  291. Binding sites for125I ET-1, ET-2, ET-3 and vasoactive intestinal contractor are present in adult rat brain and neurone-enriched primary cultures of embryonic brain cells
  292. Binding sites for iodinated endothelin-1, endothelin-2 and endothelin-3 demonstrated on human uterine glandular epithelial cells by quantitative high-resolution autoradiography
  293. Mitogenic Effects of Vasoactive Peptides on Rat Vascular Smooth Muscle Cells
  294. Endothelin-1 stimulates prostaglandin F2α release from human endometrium
  295. The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells
  296. Atrial natriuretic factor mRNA and binding sites in the adrenal gland
  297. Localisation off binding sites for iodinated endothelin and saraffotoxin peptides in mammalian tissues using quantitative receptor autoradiography
  298. Endothelin-1 mRNA is widely expressed in porcine and human tissues.
  299. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: Comparison of levels in patients with essential hypertension and normotensive control subjects
  300. Binding Sites for125I-Labelled Endothelin-1 in the Kidneys: Differential Distribution in Rat, Pig and Man Demonstrated by Using Quantitative Autoradiography
  301. Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway—II. Differential localization of dopamine and cholecystokinin receptors
  302. Comparison between brain paste and polymer [125I]standards for quantitative receptor autoradiography
  303. Effect of the formamidine insecticide chordimeform on feeding and reproduction in the noctuid moth, Spodoptera littoralis (Boisduval)
  304. Quantitative receptor autoradiography
  305. Sex-related differences in the concentration of Met-enkephalin-like immunoreactivity in the nervous system of an insect,Schistocerca gregaria, revealed by radioimmunoassay
  306. Octopamine distribution in the larvae and adults of two species of moth, Spodoptera littoralis and Manduca sexta
  307. The action of formamidines on octopamine receptors in the locust
  308. Toxicity of chlordimeform and amitraz to the egyptian cotton leafworm (Spodoptera littoralis) and the tobacco budworm (Heliothis virescens)
  309. Changes in haemolymph octopamine levels associated with food deprivation in the locust, Schistocerca gregaria
  310. Stress-induced changes in the octopamine levels of insect haemolymph
  311. Biogenic amines in the brain of the honeybee, Apis mellifera
  312. Dynamic In Vivo Imaging of Receptors in Small Animals Using Positron Emission Tomography
  313. Imaging and Characterization of Radioligands for Positron Emission Tomography Using Quantitative Phosphor Imaging Autoradiography
  314. Immunocytochemical Localization of Receptors Using Light and Confocal Microscopy With Application to the Phenotypic Characterization of Knock-Out Mice
  315. Radioligand-Binding and Molecular-Imaging Techniques for the Quantitative Analysis of Established and Emerging Orphan Receptor Systems
  316. Apelins and the Apelin Receptor
  317. Radioligand Binding Assays and Quantitative Autoradiography of Endothelin Receptors
  318. Analysis of Endothelins by Enzyme-Linked Immunosorbent Assay and Radioimmunoassay